SG11201903875QA - Selective inhibitor of exon 20 insertion mutant egfr - Google Patents
Selective inhibitor of exon 20 insertion mutant egfrInfo
- Publication number
- SG11201903875QA SG11201903875QA SG11201903875QA SG11201903875QA SG11201903875QA SG 11201903875Q A SG11201903875Q A SG 11201903875QA SG 11201903875Q A SG11201903875Q A SG 11201903875QA SG 11201903875Q A SG11201903875Q A SG 11201903875QA SG 11201903875Q A SG11201903875Q A SG 11201903875QA
- Authority
- SG
- Singapore
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- insertion mutant
- egfr
- Prior art date
Links
- 230000037431 insertion Effects 0.000 title abstract 3
- 238000003780 insertion Methods 0.000 title abstract 3
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213072 | 2016-10-31 | ||
| PCT/JP2017/037186 WO2018079310A1 (ja) | 2016-10-31 | 2017-10-13 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903875QA true SG11201903875QA (en) | 2019-05-30 |
Family
ID=62024991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903875QA SG11201903875QA (en) | 2016-10-31 | 2017-10-13 | Selective inhibitor of exon 20 insertion mutant egfr |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11857513B2 (zh) |
| EP (1) | EP3533449B1 (zh) |
| JP (1) | JP6896755B2 (zh) |
| KR (1) | KR102639585B1 (zh) |
| CN (1) | CN110191711B (zh) |
| AU (1) | AU2017350440B2 (zh) |
| BR (1) | BR112019008374A2 (zh) |
| CA (1) | CA3041015A1 (zh) |
| DK (1) | DK3533449T3 (zh) |
| ES (1) | ES2955832T3 (zh) |
| FI (1) | FI3533449T3 (zh) |
| HU (1) | HUE063712T2 (zh) |
| IL (1) | IL266239B2 (zh) |
| JO (1) | JOP20190073A1 (zh) |
| MX (1) | MX2019004969A (zh) |
| PH (1) | PH12019500957A1 (zh) |
| PL (1) | PL3533449T3 (zh) |
| PT (1) | PT3533449T (zh) |
| SG (1) | SG11201903875QA (zh) |
| TW (1) | TWI774699B (zh) |
| WO (1) | WO2018079310A1 (zh) |
| ZA (1) | ZA201902629B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| AU2019417691A1 (en) * | 2018-12-28 | 2021-07-22 | Taiho Pharmaceutical Co., Ltd. | L718 and/or L792 mutant treatment-resistant EGFR inhibitor |
| SG11202108648TA (en) | 2019-02-15 | 2021-09-29 | Taiho Pharmaceutical Co Ltd | 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative |
| CN115181104A (zh) * | 2019-09-29 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| CN116096372B (zh) * | 2020-07-09 | 2024-09-03 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| RU2007138264A (ru) | 2005-03-17 | 2009-09-10 | Новартис АГ (CH) | N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| KR101609412B1 (ko) | 2009-07-10 | 2016-04-05 | 다이호야쿠힌고교 가부시키가이샤 | 아자 2 고리형 화합물 또는 그 염 |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| US8912181B2 (en) | 2011-01-07 | 2014-12-16 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compound or salt thereof |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| SG11201402876UA (en) | 2012-02-23 | 2014-12-30 | Taiho Pharmaceutical Co Ltd | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
| CA2898274A1 (en) | 2013-02-22 | 2014-08-28 | Taiho Pharmaceutical Co., Ltd. | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
| WO2015025936A1 (ja) | 2013-08-22 | 2015-02-26 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| US10227342B2 (en) | 2014-06-19 | 2019-03-12 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| PL3677266T3 (pl) | 2017-09-01 | 2024-07-01 | Taiho Pharmaceutical Co., Ltd. | Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 |
-
2017
- 2017-06-16 JO JOP/2019/0073A patent/JOP20190073A1/ar unknown
- 2017-10-13 FI FIEP17864975.2T patent/FI3533449T3/fi active
- 2017-10-13 ES ES17864975T patent/ES2955832T3/es active Active
- 2017-10-13 WO PCT/JP2017/037186 patent/WO2018079310A1/ja unknown
- 2017-10-13 SG SG11201903875QA patent/SG11201903875QA/en unknown
- 2017-10-13 PL PL17864975.2T patent/PL3533449T3/pl unknown
- 2017-10-13 PT PT178649752T patent/PT3533449T/pt unknown
- 2017-10-13 EP EP17864975.2A patent/EP3533449B1/en active Active
- 2017-10-13 KR KR1020197015270A patent/KR102639585B1/ko active IP Right Grant
- 2017-10-13 CA CA3041015A patent/CA3041015A1/en active Pending
- 2017-10-13 HU HUE17864975A patent/HUE063712T2/hu unknown
- 2017-10-13 JP JP2018547565A patent/JP6896755B2/ja active Active
- 2017-10-13 TW TW106135203A patent/TWI774699B/zh active
- 2017-10-13 BR BR112019008374A patent/BR112019008374A2/pt unknown
- 2017-10-13 AU AU2017350440A patent/AU2017350440B2/en active Active
- 2017-10-13 CN CN201780067762.5A patent/CN110191711B/zh active Active
- 2017-10-13 MX MX2019004969A patent/MX2019004969A/es unknown
- 2017-10-13 IL IL266239A patent/IL266239B2/en unknown
- 2017-10-13 DK DK17864975.2T patent/DK3533449T3/da active
- 2017-10-31 US US16/345,792 patent/US11857513B2/en active Active
-
2019
- 2019-04-25 ZA ZA2019/02629A patent/ZA201902629B/en unknown
- 2019-04-29 PH PH12019500957A patent/PH12019500957A1/en unknown
-
2023
- 2023-11-17 US US18/512,528 patent/US20240148734A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903875QA (en) | Selective inhibitor of exon 20 insertion mutant egfr | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| PH12019501919A1 (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
| EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| TN2017000486A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| MX2017003464A (es) | Inhibidores de histona desmetilasa. | |
| JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
| MX2023011608A (es) | Metodos para inhibir ras. | |
| WO2018218197A3 (en) | ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2018008507A (es) | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| MX2020012805A (es) | Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. |